The 70-gene signature test as a prognostic and predictive biomarker in patients with invasive lobular breast cancer
Authors:
- 29 October 2021
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 191 (2) , 401-407
Abstract
Purpose Genomic expression assays provide prognostic information and guide adjuvant chemotherapy decisions for patients with estrogen receptor (ER)-positive breast cancer. Few studies have evaluated the utility of such assays for invasive lobular carcinoma (ILC). The objective of this study is to evaluate the 70-gene signature test (ST) as a prognostic and predictive tool for ILC using a national cancer database. Methods We identified patients diagnosed with stage I–III ER-positive ILC from 2004 to 2016 using the National Cancer Database. All patients underwent 70-gene ST testing. We used the Kaplan–Meier method and Cox proportional hazard analyses to determine overall survival based on genomic risk classification. We also determined the benefit of adjuvant chemotherapy for patients with high-genomic risk ILC based on 70-gene ST testing. Results We identified 2610 patients with ILC who underwent 70-gene ST testing; 280 (11%) were classified as high genomic risk. Five-year overall survival rates were significantly worse for patients classified as high risk (83%) as compared with those classified as low risk (94%, p < 0.05). In Cox models, high genomic risk was independently associated with a significantly increased hazard of death. In our Cox models of patients who were high genomic risk, adjuvant chemotherapy was not significantly associated with improved overall survival. Conclusion In this large database study, we found that the genomic risk category determined by the 70-gene ST was significantly associated with survival outcomes for patients with ILC. However, the 70-gene ST failed to predict the benefit of adjuvant chemotherapy for patients with high genomic risk.Keywords
This publication has 17 references indexed in Scilit:
- Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breastCancer, 2017
- Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancerBreast Cancer, 2017
- 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast CancerNew England Journal of Medicine, 2016
- Genomic Characterization of Primary Invasive Lobular Breast CancerJournal of Clinical Oncology, 2016
- Invasive lobular carcinoma of the breast: morphology, biomarkers and ’omicsBreast Cancer Research, 2015
- Outcomes of Sentinel Lymph Node Dissection Alone vs. Axillary Lymph Node Dissection in Early Stage Invasive Lobular Carcinoma: A Retrospective Study of the Surveillance, Epidemiology and End Results (SEER) DatabasePLOS ONE, 2014
- Distinct Clinical and Prognostic Features of Infiltrating Lobular Carcinoma of the Breast: Combined Results of 15 International Breast Cancer Study Group Clinical TrialsJournal of Clinical Oncology, 2008
- Genomic and transcriptional aberrations linked to breast cancer pathophysiologiesCancer Cell, 2006
- Clinical characteristics of different histologic types of breast cancerBritish Journal of Cancer, 2005
- Metastatic patterns of invasive lobular versus invasive ductal carcinoma of the breast.1993